Isomorphic Labs in Talks to Raise $5 Billion at a $50 Billion Valuation, Bloomberg Reports

Google’s AI drug-discovery company Isomorphic Labs is in talks to raise about $5 billion in new funding at a valuation of about $50 billion, Bloomberg reported on 4 November 2026. If the round closes at that price, it would make a company that has not yet tested a single one of its own drugs in humans worth more than many of the world’s biggest pharmaceutical firms — and it would be one of the largest private funding rounds in the history of artificial intelligence.

The talks are not finished, and the details could still change. But the numbers alone tell a story about how much faith investors now place in AI-designed medicine — and how much risk they are willing to take before a single patient has taken a pill designed by a machine.

What Bloomberg reported

Bloomberg reported late on Wednesday, 4 November, that Isomorphic Labs is negotiating a funding round of roughly $5 billion, citing people familiar with the matter who spoke on condition of anonymity because the information is not public. The round would value the London-based company at about $50 billion.

The financing has not closed, and the terms could change. Isomorphic Labs did not respond to a request for comment, and the investors expected to back the deal have not been named.

This is the second time in about a month that Bloomberg has reported on a possible Isomorphic Labs fundraising. In early October, the news agency reported that the company was in early talks to raise money at a valuation of at least $40 billion, with one person saying the round could value it at as much as $50 billion. The new report puts the figure at the top of that range — and adds a round size of about $5 billion that was not mentioned in October.

What Isomorphic Labs does

Isomorphic Labs was spun out of Google DeepMind in 2021. It was founded by Sir Demis Hassabis, the Nobel Prize-winning scientist who also leads DeepMind, to use artificial intelligence to design new medicines.

The company is built on AlphaFold, DeepMind’s AI system for predicting the three-dimensional structure of proteins. Proteins are the tiny molecular machines that do most of the work inside the human body, and their shape decides what they do. For decades, working out a protein’s shape was slow, expensive laboratory work. AlphaFold changed that by predicting protein structures from their amino-acid sequences with remarkable accuracy — work that earned Hassabis and his colleague John Jumper a share of the 2024 Nobel Prize in Chemistry.

Isomorphic Labs takes that idea one step further. Instead of only predicting the shape of proteins that already exist, it designs new molecules that could become drugs. Its platform, called the Isomorphic Drug Design Engine (IsoDDE), is a suite of AI models that predict molecular structures and how they interact, so that drug candidates can be designed and improved on a computer before any laboratory work begins.

The company has in-house drug programmes focused on cancer and immune disorders, and it works with some of the world’s biggest pharmaceutical companies. Eli Lilly signed a partnership in January 2024 worth up to $1.7 billion in milestone payments, and Novartis signed a similar deal worth up to $1.2 billion. Johnson & Johnson joined as a partner in January 2026, on terms that were not disclosed. Milestone payments are only paid if the work reaches agreed development goals.

As of May 2026, Isomorphic Labs had more than 350 staff working in London, Cambridge, Massachusetts and Lausanne.

The funding ladder so far

If the reported $5 billion round closes, it would be the company’s third big external fundraising in less than two years — and by far its biggest.

• March 2025: Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital, with GV and Alphabet taking part.
• May 2026: It closed a $2.1 billion Series B round, announced on 12 May 2026, led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund joining.
• November 2026 (in talks): About $5 billion at a valuation of about $50 billion, according to Bloomberg.

Neither of the two completed rounds came with a disclosed valuation, so there is no official benchmark to compare the $50 billion figure against. But the scale of the jump is clear: the reported new round would be about 2.4 times the size of the $2.1 billion Series B from just five months ago, and more than eight times the $600 million round from March 2025.

If the $5 billion round closes, Isomorphic Labs’ total external funding would reach about $7.7 billion in under two years.

Why investors would pay $50 billion for a company with no drug in humans yet

The most striking thing about the reported valuation is what Isomorphic Labs has not done yet. It has not tested any of its own drug candidates in humans. Its work remains in the preclinical stage — the phase of research that happens in laboratories and computer models, before a drug is given to people for the first time.

Speaking at the Bloomberg Tech conference in London on Monday, 2 November, Isomorphic Labs president Max Jaderberg said the company remains in its “first innings” — a cricket phrase meaning it is still at the very start of its journey.

So why would investors value it at $50 billion?

The first reason is the technology itself. Drug discovery is famously slow and expensive: developing a new medicine traditionally takes more than a decade and costs billions of dollars, and most candidates fail. If AI can design better drug candidates faster and predict which ones are most likely to work, it could change the economics of the whole industry. AlphaFold has already proved that AI can solve a problem — protein structure prediction — that scientists struggled with for 50 years.

The second reason is the partnerships. Deals with Eli Lilly, Novartis and Johnson & Johnson are a form of validation: the world’s biggest drug companies are willing to pay hundreds of millions of dollars in milestone payments to use Isomorphic Labs’ technology. Those partnerships also bring in money and expertise while the company’s own drug programmes are still in the laboratory.

The third reason is the market. Grand View Research forecasts that the AI drug discovery market will be worth $13.8 billion by 2033, up from $2.3 billion in 2025. A single company valued at $50 billion would be worth about 3.6 times the entire sector’s projected sales that year — a sign that investors expect Isomorphic Labs to capture a very large share of that market, or to grow it far beyond current forecasts.

But the valuation is, for now, a bet on a promise. A drug designed by AI still has to pass the same clinical trials as any other drug. A molecule that looks perfect on a computer can still fail in the human body, and most drug candidates do.

The competition is heating up

Isomorphic Labs is not the only company using AI to design drugs, and its rivals are raising money at far lower valuations — which makes the $50 billion figure stand out even more.

Chai Discovery, another AI drug-discovery startup, raised $400 million in July 2026 at a $3.8 billion valuation. That makes Isomorphic Labs’ reported valuation about 13 times higher. Basecamp Research, a London-based company in the same field, raised $140 million at an $800 million valuation in September — making Isomorphic Labs more than 60 times bigger by that measure.

The competition is not limited to startups. Bloomberg also reported that Isomorphic Labs is competing with OpenAI, which launched a life sciences research model this year. The AI industry’s biggest names are all moving into biology, and the race to design the first AI-created drug that works in patients is now a crowded one.

That race is also taking place against a difficult backdrop for AI stocks. Wall Street suffered a sharp sell-off on 5 November, with the Nasdaq falling 5.52% into correction territory as investors questioned whether the AI boom is moving too fast — a reminder that even the hottest areas of technology can cool quickly when confidence wobbles.

What happens next

Two things are worth watching in the coming weeks.

The first is the funding round itself. If Isomorphic Labs confirms the raise, the key details will be who leads it and how much of the company the new money buys. A $5 billion investment at a $50 billion valuation would be roughly 10% of the company if the valuation includes the new money, or about 9% if it does not. Either way, it would be one of the largest single investments ever made in a private AI company.

The second is the clinical trial deadline. Demis Hassabis said in January 2026 that he expected the company’s first clinical trials to begin before the end of the year. That timetable has already slipped once before — a trial that was expected in 2025 did not happen — so the coming weeks will test whether the company can finally move a drug candidate from the computer into human testing. A trial would not prove that the drug works, but it would show that Isomorphic Labs can get a candidate into human testing at all.

If another delay follows, the $50 billion valuation would rest on partnerships and technical claims that have not yet been validated in patients. If the trials begin on schedule, it would be the moment the company’s promise starts to be tested in the real world.

For now, the talks are only talks. But the message from investors is already clear: they believe AI-designed medicine is worth betting billions on — before a single patient has taken the medicine.

FAQ

What is Isomorphic Labs?

Isomorphic Labs is an artificial intelligence company spun out of Google DeepMind in 2021. It uses AI to design new medicines, building on AlphaFold, DeepMind’s system for predicting protein structures. It is led by Nobel Prize-winning scientist Sir Demis Hassabis, who also leads Google DeepMind.

How much money is Isomorphic Labs trying to raise?

Bloomberg reported on 4 November 2026 that the company is in talks to raise about $5 billion at a valuation of about $50 billion. The financing has not closed and the terms could change.

Has Isomorphic Labs tested any of its drugs in humans?

No. Its drug programmes remain in the preclinical stage, and it has not yet tested its own drug candidates in humans. Demis Hassabis said in January 2026 that he expected the first clinical trials to begin by the end of the year.

How much has Isomorphic Labs raised before?

The company raised $600 million in March 2025 and $2.1 billion in May 2026. If the reported $5 billion round closes, its total external funding would reach about $7.7 billion in under two years.

Who are Isomorphic Labs’ partners?

Eli Lilly (January 2024, worth up to $1.7 billion in milestone payments), Novartis (up to $1.2 billion in milestone payments) and Johnson & Johnson (January 2026, terms undisclosed).

Why is a $50 billion valuation surprising?

Because the company has no drug in human trials yet. Its rivals are valued far lower: Chai Discovery raised money at a $3.8 billion valuation in July 2026, and Basecamp Research at $800 million in September. The $50 billion figure is a bet on the technology’s future, not on proven results.

Conclusion

The reported $5 billion fundraising would put Isomorphic Labs among the most valuable private companies in the world — and it would do so before the company has tested a single drug in a human being. That is either a sign of extraordinary confidence in AI-designed medicine, or a sign of how much money is chasing the idea.

The technology behind the company is real and remarkable: AlphaFold solved a scientific problem that had stood for half a century, and the world’s biggest drug companies are paying to use Isomorphic Labs’ platform. But the hardest test is still ahead. Designing a molecule on a computer is one thing; proving it is safe and effective in patients is another — and that is where most drug candidates fail.

The end of 2026 will be the moment of truth. If the first clinical trials begin on schedule, the $50 billion valuation will start to look like a bet on something real. If they slip again, investors may start asking harder questions about what, exactly, they are paying for.

Sources

• Tech Funding News, “Report: Isomorphic Labs in talks to raise $5B at $50B valuation”, 5 November 2026 — https://techfundingnews.com/isomorphic-labs-5b-raise-50b-valuation-first-clinical-trial/
• Dealroom, “DeepMind spinout Isomorphic Labs in talks to raise about $5B at a $50B valuation” — https://dealroom.co/news/161156-deepmind-spinout-isomorphic-labs-in-talks-to-raise-about-5b-at-a-50b-val/
• The World Insiders, “Isomorphic Labs seeks about $5 billion in funding talks” — https://tech.theworldinsiders.com/news/isomorphic-labs-seeks-about-5-billion-in-funding-talks/n1726
• TokenPost, “Isomorphic Labs funding talks” — https://www.tokenpost.com/news/business/49671
• FourWeekMBA, “AI: Google’s Isomorphic in talks for $5B at $50B — 2.4x May round” — https://fourweekmba.com/ai-googles-isomorphic-in-talks-for-5b-at-50b-2-4x-may-round/

This article is for general information and education only. It is not legal or financial advice.